TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ATP content in ischemic myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: inosine/adenosine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ST-segment shifting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: gingivitis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of spasm freedom at three months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Tolerance to circuit breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product-related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: MEF25
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: daytime asthma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete clearing of anogenital warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in the number and size of anogenital warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: total morphine requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Noninvasive breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of 25(OH)D deficient patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTH levels changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean pentagastrin-stimulated acid output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean time with pH > 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean time with pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in outcome measures for plantar fasciitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median duration of analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mandibular function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum interincisal opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative non-recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Quality of depression care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Centralization of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neck stiffness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity of hepatitis A
Endpoint domain: Mortality/survival
Primary endpoint: protective efficacy of the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: attack rate of HAV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: therapeutical efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: EuroQOL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intermodality agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second primary malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Figures of merit for noise reduction methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bodily pain reduction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SNR of abdominal aorta, pancreas, and abdominal wall fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute oral bioavailability of imidafenacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of hereditary cancer
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mental Fatigue Scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive function scores (MMSE, Digit Symbol Substitution Test, etc.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to stone expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WRS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hearing gains in PTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for anti‐anginal medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean 24-h leucine oxidation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean 24-h leucine balances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: targeted injury incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower-limb incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left ventricular end-systolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Height at 12 years of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blood pressure at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: calculated upper body vascular resistance at 10 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Success rate for treating bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V˙E/V˙CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aldosterone escape
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: high urinary aldosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: housing tenure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced hospitalisation costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Magnitude of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postpartum hemorrhage (≥ 500 mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and specificity of electrode systems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean percentage change in PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reliability of course-based classification system for major depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: necessity of routine oxygen humidification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: short‐ and long‐term abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: live birth rates per oocyte retrieval
Endpoint domain: Mortality/survival
Primary endpoint: proportions of good quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Factor VIIc activity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in anagen hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in telogen hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in catagen hairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clearance of flat warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Same-day return after angiography and/or PCI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Major events within 30 days
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of Response (LOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Involuntary Deviation (IVD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to EI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalent STI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: recurrence of major depressive episodes
Endpoint domain: Mortality/survival
Primary endpoint: constipation
Endpoint domain: Adverse events/effects
Primary endpoint: hospital readmission within 30 days after SNF discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction of siDBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: retentive performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrophysiological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of big IGF‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cumulative proportion of treatment failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blinded-assessor otorrhea treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating of acceptance of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 3-year composite of major adverse cardiac events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Composite of nonfatal myocardial infarction, nonfatal ischemic stroke, major amputation, and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction with overall implant treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of toxoplasmosis
Endpoint domain: Adverse events/effects
Primary endpoint: Right atrial area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right ventricular area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TAPSE increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 17-hydroxyprogesterone (17-OHP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: clinical duration of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary NAGA excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease in fluorescence loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of mipomersen
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced hippocampal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: serum calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urine deoxypyridinoline (DPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HARS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychological functioning factor of SAT-P
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: social functioning factor of SAT-P
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Improvement scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: nonfatal re-MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiographic ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Propofol consumption for anesthesia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hetero-evaluation of arm movement during propofol injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face reaction at venous access placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of hyperphosphatemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of hypercalcaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Ep-CAM-specific IgG antibodies production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ep-CAM-specific proliferative T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon-gamma-secreting cells detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: self-care activation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Satisfaction Questionnaire for Medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oral clearance of rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of root surface calculus free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in MHAQ scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in health-related quality of life (SF-36 physical component score)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients eligible for SGLT-2 inhibitor therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPM (performance component)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Workplace physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) at WT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early bactericidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to recognize either the trachea or the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVLWI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dryness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preference for HHFO₂
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fracture resistance of composite resin crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident atherosclerosis risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incident cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrical activity of the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG beta activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Development of NNRTI and NRTI resistance mutations
Endpoint domain: Adverse events/effects
Primary endpoint: Shear bond strength values (MPa)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type II endoleak occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative pulmonary embolism (PE)
Endpoint domain: Mortality/survival
Primary endpoint: Change in FEV1 percent predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum calprotectin levels predictive of PEx risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete aneurysm occlusion at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of complete aneurysm occlusion at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: composite of cardiac death, target-vessel MI and target lesion revascularisation
Endpoint domain: Mortality/survival
Primary endpoint: impulsiveness on CPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: variability of steering in the standard driving course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: driving speed during the obstacle course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen synthesis markers (PINP, PIIINP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of moderate pain at discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Epinephrine levels at 3.5 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Meeting intermediate outcomes targets for hemoglobin A(1c, low-density lipoprotein cholesterol, and blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of morning stiffness (DMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest expansion (CE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global well being of the patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relationship between HbA(1c) and PG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased sexual functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased sexual distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total symptom scores on the Present Functioning Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tourniquet pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in the number of times per month discussing risks of medication use during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Postoperative nausea and vomiting (PONV) episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Requirements of antiemetic drugs
Endpoint domain: Adverse events/effects
Primary endpoint: subjective stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Psychological assessment scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mask displacements during maintenance of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gastric insufflation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change from baseline in total score for objective signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate or severe anorexia
Endpoint domain: Adverse events/effects
Primary endpoint: Weakness
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective fever
Endpoint domain: Adverse events/effects
Primary endpoint: Mean temperatures of infusers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: co-trimoxazole prophylaxis receipt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: tuberculosis diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of root caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Mechanical responses to 80‐ and 20‐Hz stimulation (P80 and P20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: asthma symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in opioid analgesic requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in plasma norepinephrine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes